ASH1LClinical & Research HubSearchConnectFamilies · Clinical · Research

CLINICAL ATLAS · AREA 11

Immune / skin / mucosal

Open the exact information count, clinical terms, source boundaries, and next measurement for this area. Counts describe information availability—not prevalence.

HOW TO READ THE COUNTSOne key applies to all 15 areas.Each area places all 63 connected people into one mutually exclusive category. These groups describe the information available; they are not prevalence estimates.

A finding is reported
At least one feature is reported, without an explicitly normal or uncertain item in the same area.
A finding plus normal or uncertain information
A reported feature appears alongside an explicitly normal result or an unresolved observation.
Only explicitly normal results
The available information records a normal or negative result without a reported feature in the area.
Only uncertain information
An observation remains unresolved and no confirmed feature is recorded in the area.
Area not addressed
The available information does not answer this broad area; this is not a negative result.
AREA 11 / 15Body systems · Barrier and response

Information available for Immune / skin / mucosal

What is measurable—and what remains only temporally associated?

Infection history, antibody-response testing, mucosal findings, skin, wound healing, allergy, inflammatory testing, and recovery after an immune challenge.

Primary chapter · Immune, skin & mucosa →
Information available
38 / 63
Original source documents available
11
Area not addressed
25 / 63
Counts for this area
Immune / skin / mucosal: mutually exclusive information groups for all 63 connected people, using the shared key above.
What is recordedPeople
A finding is reported19
A finding plus normal or uncertain information15
Only explicitly normal results3
Only uncertain information1
Area not addressed25
Total people63

38 with information + 25 not addressed = 63. For 11 people, at least one item in this area is supported by an original clinical or laboratory source addressing the area.

WHAT THE INFORMATION SHOWS

Recurrent infection and ENT burden, mucosal fragility, skin or healing observations, and selected laboratory findings are present but heterogeneous.

HOW TO READ IT

The available histories raise questions worth studying about immune, skin, and mucosal health; they do not establish a shared ASH1L immune disorder.

NEXT MEASUREMENT

Define infection type and frequency, barrier or mucosal phenotype, objective immune testing when indicated, treatment exposure, vaccine-response question, and recovery.

Clinical terms found in the available information

Infection & antibody response

  • recurrent viral or bacterial illness
  • ENT or skin infection burden
  • anti-infective exposure
  • immunoglobulin and antibody-response testing
  • specialist interpretation over time

Inflammation & mucosa

  • systemic inflammatory markers
  • selected immune testing
  • oral, ENT, GI, or urinary mucosal findings
  • allergy or atopy
  • normal markers retained for comparison

Skin, vascular & repair

  • eczema, itching, flushing, or skin differences
  • bruising
  • wound healing or scarring
  • vascular or hemostatic observations
  • fracture and mobility context
Where the information comes from and what it cannot show

WHERE THIS INFORMATION CAME FROM

  • immunology record
  • laboratory data
  • infection timeline
  • dermatology
See the sitewide evidence framework →